A

Arizona Neuroscience Research, LLC | Phoenix, AZ

Research site

(Unclaimed)

Location

3805 E Bell Rd, Suite 2400, Phoenix, Arizona, United States of America

Site insights

Top conditions

Top treatments

ABP-450

Ocrelizumab

PIPE-307

Simufilam

Ofatumumab

ABP-19000

Bafiertam

JZP385

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 11 total trials

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (OLERO)

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche...

Active, not recruiting

Multiple Sclerosis

Drug: Ocrelizumab

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease (REFOCUS-ALZ)

A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 we...

Active, not recruiting

Alzheimer Disease

Drug: Placebo

Drug: Simufilam

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. (AGNOS)

This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of...

Active, not recruiting

Relapse Remitting Multiple Sclerosis

Drug: Ofatumumab

Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects with Relapsing-Remitting Multiple Sclerosis (VISTA)

This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized...

Enrolling

Relapsing Remitting Multiple Sclerosis

Drug: Placebo

Drug: PIPE-307 Dose A